Information only. Not medical advice, and not a recommendation to use any compound. We do not sell or supply any compound Speak to a doctor before any decision about your health Information only. Not medical advice, and not a recommendation to use any compound. We do not sell or supply any compound Speak to a doctor before any decision about your health Information only. Not medical advice, and not a recommendation to use any compound. We do not sell or supply any compound Speak to a doctor before any decision about your health
Genexis Health
Immune Zadaxin

Thymosin Alpha-1

Also known as Tα1 · Thymalfasin · developed by SciClone

Phase 3 trials

Large randomised trials in humans are complete or under way, but the compound is not licensed. Efficacy and common adverse effects are reasonably well characterised; long-term safety may not be.

Prescription medicine Licensed and available only on prescription in the UK, EU and US. Supply without a prescription is illegal.
Illustration only. Not a photograph of a product, and not an offer of supply — Genexis Health does not sell or supply Thymosin Alpha-1.

What it is

A 28-residue peptide originally isolated from thymus tissue, with a genuine clinical history — approved in a number of countries, though not in the UK, EU or US.

How it is thought to work

Modulates immune function through effects on toll-like receptor signalling, T-cell maturation and dendritic cell activity.

What the studies found

  • Approved for hepatitis B in several countries

    Licensed in over 30 countries, largely for chronic hepatitis B and as a vaccine adjuvant, on the basis of randomised trials.

  • Studied in sepsis and in COVID-19

    Trials in sepsis and observational work during COVID-19 produced mixed results. No indication was established in Western regulatory markets.

What the evidence does not show

  • Not approved in the UK, EU or US, despite a long development history — an important signal about how those regulators assessed the evidence.
  • Trial quality is variable and much of it is older.
  • Claims about general immune enhancement in healthy people are not supported by the trials, which studied specific disease populations.

Reported risks and adverse effects

  • Generally well tolerated in trials; injection site reactions are the most common effect.
  • Immune modulation carries theoretical concern in autoimmune disease.
  • Its safety record comes from supervised clinical use in defined patient groups.

This is a summary of what has been reported in the literature, not a complete safety profile. For anything concerning your own health, speak to a doctor.

Regulatory status

Licensed in a number of countries including parts of Asia and Latin America. Not approved in the UK, EU or US.

Where it acts

The sites below are where Thymosin Alpha-1 is understood to act, paired with what was actually measured there and in whom. A site on this diagram means a compound acts there — not that a benefit is established.

Drag to turn · tap an organ

12
Stylised illustration. Marker positions are indicative, not anatomically precise.
  1. Modulates toll-like receptor signalling, T-cell maturation and dendritic cell activity.

    What was measuredApproved for hepatitis B in several countries. Studied in sepsis and in COVID-19, where results are mixed and trials are heterogeneous.

  2. Used as an adjunct in chronic hepatitis B.

    What was measuredThe approval in several countries rests on hepatitis B, not on the sepsis or COVID-19 work.